MorphoSys AG – NASDAQ:MOR
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
MorphoSys AG stock price monthly change
+2.06%
month
MorphoSys AG stock price quarterly change
+3.98%
quarter
MorphoSys AG stock price yearly change
+148.35%
year
MorphoSys AG key metrics
Market Cap | 2.85B |
Enterprise value | 585.74M |
P/E | -3.65 |
EV/Sales | 2.10 |
EV/EBITDA | 4.20 |
Price/Sales | 1.98 |
Price/Book | 3.50 |
PEG ratio | -0.05 |
EPS | -2.23 |
Revenue | 203.58M |
EBITDA | -327.75M |
Income | -460.26M |
Revenue Q/Q | -55.80% |
Revenue Y/Y | -31.94% |
Profit margin | -54.3% |
Oper. margin | -79.34% |
Gross margin | 82.52% |
EBIT margin | -79.34% |
EBITDA margin | -160.99% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMorphoSys AG stock price history
MorphoSys AG stock forecast
MorphoSys AG financial statements
| Jun 2023 | 53.16M | -73.96M | -139.13% |
|---|---|---|---|
| Sep 2023 | 63.8M | -119.6M | -187.46% |
| Dec 2023 | 59.07M | 48.26M | 81.7% |
| Mar 2024 | 27.53M | -314.96M | -1143.67% |
| 2025 | 325.26M | -115.69M | -35.57% |
|---|---|---|---|
| 2026 | 424.76M | -31.37M | -7.39% |
| 2027 | 608.14M | -157.48M | -25.9% |
| 2028 | 1.09B | 134.84M | 12.35% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-16 | -2.10001 | -0.91 |
|---|---|---|
| 2023-03-17 | -13.82882 | 2.41 |
| Jun 2023 | 2142502407 | 2.11B | 98.52% |
|---|---|---|---|
| Sep 2023 | 2100982302 | 2.16B | 103.19% |
| Dec 2023 | 2026311213 | 1.97B | 97.58% |
| Mar 2024 | 1831530557 | 2.09B | 114.29% |
| Jun 2023 | -125.96M | 23.24M | -4.67M |
|---|---|---|---|
| Sep 2023 | -33.67M | 34.90M | -1.71M |
| Dec 2023 | -56.35M | -61.59M | 95.03M |
| Mar 2024 | -64.42M | 36.24M | -942.47K |
MorphoSys AG alternative data
| Aug 2023 | 623 |
|---|---|
| Sep 2023 | 544 |
| Oct 2023 | 544 |
| Nov 2023 | 544 |
| Dec 2023 | 544 |
| Jan 2024 | 544 |
| Feb 2024 | 544 |
| Mar 2024 | 524 |
| Apr 2024 | 524 |
| May 2024 | 524 |
| Jun 2024 | 464 |
| Jul 2024 | 464 |
MorphoSys AG other data
5.40%
-31.08%
of MOR is owned by hedge funds
15
-11
1.84M
-10.34M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 25 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 4 May 2020 Issue date: 4 Aug 2022 |
Application Filling date: 22 Mar 2022 Issue date: 7 Jul 2022 |
Grant Utility: Peptide libraries Filling date: 8 Sep 2020 Issue date: 7 Jun 2022 |
Grant Utility: Anti-CD19 antibody formulations Filling date: 27 Jun 2017 Issue date: 7 Jun 2022 |
Application ANTI-CD38 ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF AUTOANTIBODY-MEDIATED AUTOIMMUNE DISEASE Filling date: 13 Mar 2020 Issue date: 12 May 2022 |
Application Filling date: 10 Jan 2022 Issue date: 5 May 2022 |
Application Filling date: 13 Mar 2020 Issue date: 5 May 2022 |
Application Filling date: 13 Dec 2019 Issue date: 14 Apr 2022 |
Application Filling date: 8 Dec 2021 Issue date: 24 Mar 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 16 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 6 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jean-Paul Kress M.D. (1965) Chairman of Management Board, MD & Chief Executive Officer | $2,340,000 |
Dr. Malte Peters M.D. (1962) Chief R&D Officer and Member of the Management Board | $1,340,000 |
MorphoSys: Hold Rating Until The Novartis Deal Closes
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case
MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis
MorphoSys: Buying Constellation Was A Desperate Measure
MorphoSys: Still Positive Moving Into Pelabresib Data (Maintaining Buy Rating)
MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run
MorphoSys: Morphing Prospects, Q1 2023, Rising From The Ashes
-
When is MorphoSys AG's next earnings date?
Unfortunately, MorphoSys AG's (MOR) next earnings date is currently unknown.
-
Does MorphoSys AG pay dividends?
No, MorphoSys AG does not pay dividends.
-
How much money does MorphoSys AG make?
MorphoSys AG has a market capitalization of 2.85B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 14.37% to 238.28M US dollars. MorphoSys AG made a loss 189.73M US dollars in net income (profit) last year or $2.41 on an earnings per share basis.
-
What is MorphoSys AG's stock symbol?
MorphoSys AG is traded on the NASDAQ under the ticker symbol "MOR".
-
What is MorphoSys AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MorphoSys AG?
Shares of MorphoSys AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MorphoSys AG's key executives?
MorphoSys AG's management team includes the following people:
- Dr. Jean-Paul Kress M.D. Chairman of Management Board, MD & Chief Executive Officer(age: 60, pay: $2,340,000)
- Dr. Malte Peters M.D. Chief R&D Officer and Member of the Management Board(age: 63, pay: $1,340,000)
-
How many employees does MorphoSys AG have?
As Jul 2024, MorphoSys AG employs 464 workers, which is 11% less then previous quarter.
-
When MorphoSys AG went public?
MorphoSys AG is publicly traded company for more then 7 years since IPO on 19 Apr 2018.
-
What is MorphoSys AG's official website?
The official website for MorphoSys AG is morphosys.com.
-
How can i contact MorphoSys AG?
MorphoSys AG can be reached via phone at +49 89 899270.
MorphoSys AG company profile:
MorphoSys AG
morphosys.comExchange:
NASDAQ
Full time employees:
464
Industry:
Biotechnology
Sector:
Healthcare
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Semmelweisstrasse 7
Planegg, 82152
Planegg, 82152
CIK: 0001340243
ISIN: US6177602025
CUSIP: 617760202
